Arcadia Biosciences Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
RKDA$0.17-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and share data)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues: | ||
| Product | $5,313 | $6,422 |
| License | 17 | 879 |
| Royalty | — | 117 |
| Total revenues | 5,330 | 7,418 |
| Operating expenses (income): | ||
| Cost of revenues | 3,300 | 6,101 |
| Research and development | 1,387 | 1,509 |
| Gain on sale of Verdeca | — | (1,138) |
| Impairment of intangible assets | — | 141 |
| Change in fair value of contingent consideration | — | (70) |
| Gain on sale of property and equipment | (40) | (314) |
| Impairment of property and equipment | — | 160 |
| Impairment of ROU asset | 113 | — |
| Selling, general and administrative | 14,508 | 15,036 |
| Total operating expenses | 19,268 | 21,425 |
| Loss from operations | (13,938) | (14,007) |
| Interest income | 695 | 289 |
| Other income, net | 48 | 9 |
| Valuation loss on March 2023 PIPE | (6,076) | — |
| Change in fair value of common stock warrant and option liabilities | 6,544 | 3,209 |
| Issuance and offering costs allocated to liability classified options | (430) | (314) |
| Net loss from continuing operations before income taxes | (13,157) | (10,814) |
| Income tax expense | (8) | (14) |
| Net loss from continuing operations | (13,165) | (10,828) |
| Net loss from discontinued operations | (821) | (4,784) |
| Net loss | (13,986) | (15,612) |
| Net loss attributable to non-controlling interest | (5) | (236) |
| Net loss attributable to common stockholders | $(13,981) | $(15,376) |
| Net loss per share attributable to common stockholders: | ||
| Basic and diluted from continuing operations | $(10.64) | $(17.67) |
| Basic and diluted from discontinued operations | $(0.66) | $(7.98) |
| Weighted-average number of shares used in per share calculations: | ||
| Basic and diluted | 1,236,934 | 599,389 |
| Other comprehensive income, net of tax | ||
| Unrealized gains on available-for-sale securities | $101 | $— |
| Other comprehensive income | $101 | $— |
| Comprehensive loss attributable to common stockholders | $(13,880) | $(15,376) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.